MCID: MLT020
MIFTS: 85

Multiple Sclerosis

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Multiple Sclerosis

MalaCards integrated aliases for Multiple Sclerosis:

Name: Multiple Sclerosis 53 37 12 72 49 24 50 71 36 51 40 41 14 69
Ms 53 49 24 71
Multiple Sclerosis, Disease Progression, Modifier of 53 13
Disseminated Sclerosis 53 24
Multiple Sclerosis Modifier of Disease Progression 28
Multiple Sclerosis, Susceptibility to, 1 53
Multiple Sclerosis, Susceptibility to 53
Generalized Multiple Sclerosis 12
Multiple Sclerosis 1 53
Insular Sclerosis 12

Characteristics:

OMIM:

53
Inheritance:
multifactorial

Miscellaneous:
onset 20-55 years of age
women affected more than men (3:2)
association with the hla-drb1*1501-dqb1*0602 haplotype has been repeatedly demonstrated in high-risk (northern european) populations.


HPO:

31
multiple sclerosis:
Inheritance multifactorial inheritance


Classifications:



Summaries for Multiple Sclerosis

NINDS : 50 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye.  Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance.  These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis.  Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations.  Some may also experience pain.  Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked.  Depression is another common feature of MS.

MalaCards based summary : Multiple Sclerosis, also known as ms, is related to relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis, and has symptoms including muscle weakness, diplopia and emotional lability. An important gene associated with Multiple Sclerosis is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs 4-Aminopyridine and Interferon beta-1b have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are hematopoietic system and cellular

UniProtKB/Swiss-Prot : 71 Multiple sclerosis: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

NIH Rare Diseases : 49 Multiple sclerosis (MS) is a degenerative disorder that affects the central nervous system, specifically the brain and the spinal cord. The disorder is characterized by destruction of the myelin, the fatty tissue that surrounds and protects the nerve fibers and promotes the transmission of nerve impulses, and damage to nerve cells. The symptoms vary widely from person to person, and may include sensory disturbances in the limbs, problems with muscle control, tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness, difficulty walking, poor bladder control, and vision problems. Most patients have periods during which they have symptoms (clinical attacks). The clinical attacks are typically followed by periods without any symptoms (remission). After several years, the symptoms worsen continuously. Multiple sclerosis is considered an autoimmune disorder but the exact cause is unknown. Risk factors for developing multiple sclerosis include genetic factors like changes in the HLA-DRB1 gene and in the IL7R gene and environmental factors, such as exposure to the Epstein-Barr virus, low levels of vitamin D, and smoking. The goal of treatment of MS is to decrease attacks and the inflammation within the central nervous system. Last updated: 11/21/2015

MedlinePlus : 40 Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include Visual disturbances Muscle weakness Trouble with coordination and balance Sensations such as numbness, prickling, or "pins and needles" Thinking and memory problems No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk. There is no single test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

Genetics Home Reference : 24 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.

Disease Ontology : 12 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

Wikipedia : 72 Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the... more...

Description from OMIM: 126200

Related Diseases for Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 614)
# Related Disease Score Top Affiliating Genes
1 relapsing-remitting multiple sclerosis 35.0 ICAM1 IFNB1 IL17A MBP MOG
2 primary progressive multiple sclerosis 34.9 ICAM1 IFNB1 IL7R MBP MOG
3 multiple sclerosis 3 34.8 IL7R MS3
4 pediatric multiple sclerosis 34.6 HLA-DQB1 HLA-DRB1 ITGA4 MOG
5 neuromyelitis optica 34.0 HLA-DRB1 IL17A MBP MOG
6 optic neuritis 33.4 HLA-DRB1 MBP MOG
7 acute disseminated encephalomyelitis 33.2 HLA-DQB1 HLA-DRB1 MBP MOG
8 balo concentric sclerosis 33.1 IFNB1 MBP MOG
9 allergic encephalomyelitis 33.1 MBP MOG
10 nervous system disease 33.0 APOE IFNB1 MBP MOG
11 progressive multifocal leukoencephalopathy 32.8 ITGA4 MBP PDCD1
12 myelitis 31.6 IL17A MBP MOG
13 demyelinating disease 31.3 ICAM1 IFNB1 IL17A IL7R MBP MOG
14 uveitis 31.3 CTLA4 ICAM1 IL17A
15 rheumatoid arthritis 31.3 CIITA CTLA4 HLA-DQB1 HLA-DRB1 ICAM1 IL17A
16 internuclear ophthalmoplegia 31.3 IFNB1 MBP MOG
17 autoimmune disease 31.2 CIITA CTLA4 HLA-DQB1 HLA-DRB1 IL17A MBP
18 polyradiculoneuropathy 31.1 IL17A MBP TNFRSF1A
19 inflammatory bowel disease 31.1 CTLA4 HLA-DQB1 HLA-DRB1 ICAM1 IL17A ITGA4
20 chronic inflammatory demyelinating polyradiculoneuropathy 31.1 IFNB1 IL17A MBP
21 systemic lupus erythematosus 31.0 CTLA4 HLA-DQB1 HLA-DRB1 ICAM1 IFNB1 IL17A
22 central nervous system disease 31.0 APOE IFNB1 IL17A MBP MOG
23 alexia 30.9 APOE MBP
24 spinal cord disease 30.7 ERVW-1 MBP MOG
25 panuveitis 30.7 HLA-DQB1 HLA-DRB1 IL17A
26 guillain-barre syndrome 30.5 HLA-DQB1 MBP TNFRSF1A
27 autoimmune hepatitis 30.4 CTLA4 HLA-DQB1 HLA-DRB1 PDCD1
28 myocarditis 30.4 HLA-DQB1 ICAM1 IL17A
29 psoriatic arthritis 30.2 HLA-DRB1 IL17A TNFRSF1A
30 marburg acute multiple sclerosis 12.5
31 secondary progressive multiple sclerosis 12.4
32 tumefactive multiple sclerosis 12.3
33 progressive relapsing multiple sclerosis 12.3
34 multiple sclerosis 5 12.2
35 disseminated sclerosis with narcolepsy 12.0
36 multiple sclerosis 2 12.0
37 multiple sclerosis 4 12.0
38 multiple sclerosis-ichthyosis-factor viii deficiency syndrome 11.9
39 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.5
40 trigeminal neuralgia 11.4
41 pars planitis 11.3
42 spasticity 11.2
43 cerebral atrophy 11.2
44 tremor 11.2
45 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.1
46 foot drop 11.1
47 leber hereditary optic neuropathy 11.1
48 dysphagia 11.1
49 retinal vasculitis 11.1
50 pseudobulbar affect 11.1

Comorbidity relations with Multiple Sclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis:



Diseases related to Multiple Sclerosis

Symptoms & Phenotypes for Multiple Sclerosis

Symptoms via clinical synopsis from OMIM:

53
Neurologic Peripheral Nervous System:
weakness
incoordination
paresthesias
sensory loss

Neurologic Central Nervous System:
emotional lability
depression
spasticity
high intensity area in white matter on head mri
cognitive dysfunction
more
Laboratory Abnormalities:
increased csf immunoglobulin levels
oligoclonal bands in csf
myelin basic protein in csf

Head And Neck Eyes:
diplopia
vision loss, monocular

Genitourinary Bladder:
incomplete bladder emptying
incontinence
hesitancy


Clinical features from OMIM:

126200

Human phenotypes related to Multiple Sclerosis:

31 (show all 10)
# Description HPO Frequency HPO Source Accession
1 muscle weakness 31 HP:0001324
2 diplopia 31 HP:0000651
3 emotional lability 31 HP:0000712
4 spasticity 31 HP:0001257
5 paresthesia 31 HP:0003401
6 incoordination 31 HP:0002311
7 urinary incontinence 31 HP:0000020
8 urinary hesitancy 31 HP:0000019
9 cns demyelination 31 HP:0007305
10 depressivity 31 HP:0000716

UMLS symptoms related to Multiple Sclerosis:


sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, muscle cramp, hemiplegia, headache, back pain

MGI Mouse Phenotypes related to Multiple Sclerosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 APOE CIITA CTLA4 HLA-DQB1 ICAM1 IFNB1
2 cellular MP:0005384 10.2 IL7R ITGA4 MBP MOG NR1H3 PDCD1
3 endocrine/exocrine gland MP:0005379 10.14 APOE CIITA CTLA4 HLA-DQB1 ICAM1 IL17A
4 immune system MP:0005387 10.13 CIITA CTLA4 HLA-DQB1 ICAM1 IFNB1 IL17A
5 homeostasis/metabolism MP:0005376 10.1 APOE CIITA CTLA4 HLA-DQB1 ICAM1 IFNB1
6 digestive/alimentary MP:0005381 9.98 HLA-DQB1 ICAM1 IL17A PTPRC TNFRSF1A APOE
7 liver/biliary system MP:0005370 9.7 PDCD1 PTPRC TNFRSF1A APOE CTLA4 HLA-DQB1
8 normal MP:0002873 9.56 CIITA CTLA4 HLA-DQB1 IFNB1 IL7R MBP
9 respiratory system MP:0005388 9.17 APOE CTLA4 HLA-DQB1 IL17A PDCD1 PTPRC

Drugs & Therapeutics for Multiple Sclerosis

Drugs for Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 625)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Phase 1 504-24-5 1727
2
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
4
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 189261-10-7
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
9
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
10
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
12
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
13
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
14 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
15
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
16
Menthol Approved Phase 4,Phase 1,Early Phase 1 2216-51-5 16666
17
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 216503-57-0
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
19
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
20
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3 112111-43-0
21
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3 68693-11-8 4236
22
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 6251 453
23
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
24
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
25
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
26
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
27 Piracetam Approved, Investigational Phase 4 7491-74-9
28
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
29
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
30
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
31
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
32
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
33
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
34
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
35
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
36
Ethanol Approved Phase 4,Phase 3 64-17-5 702
37 Peppermint oil Approved, Investigational Phase 4,Phase 3
38
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
39
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
40
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
41
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
42
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
43
Cetirizine Approved Phase 4,Phase 1 83881-51-0 2678
44
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
45
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
46
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
47
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
48
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
49
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
50
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447

Interventional clinical trials:

(show top 50) (show all 1785)

# Name Status NCT ID Phase Drugs
1 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
2 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
3 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
4 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
5 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
6 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
7 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
8 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
9 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
10 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
11 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
12 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
13 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
14 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
15 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
16 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
17 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
18 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
19 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
20 Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients Completed NCT01658384 Phase 4
21 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4 Fingolimod;Standard MS DMTs
22 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
23 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
24 Levetiracetam in Central Pain in Multiple Sclerosis(MS) Completed NCT00423527 Phase 4 levetiracetam
25 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
26 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
27 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
28 Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis Completed NCT00468182 Phase 4 Interferon-beta 1b (Betaseron)
29 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
30 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
31 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
32 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
33 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Completed NCT01480076 Phase 4 Fampridine
34 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4 IFN-β-1a (Rebif®)
35 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
36 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
37 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
38 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
39 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera Completed NCT02410278 Phase 4 dimethyl fumarate;montelukast;Placebo
40 A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis Completed NCT01356940 Phase 4 dalfampridine ER;placebo
41 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4 Anesthetic Topical Adhesive Synera
42 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
43 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis Completed NCT00381264 Phase 4 Cesamet™ (nabilone)
44 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
45 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
46 Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients Completed NCT00262314 Phase 4
47 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
48 Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment Completed NCT00942214 Phase 4 Natalizumab
49 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
50 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4 Interferon beta 1a, oral doxycycline

Search NIH Clinical Center for Multiple Sclerosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Sclerosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Multiple Sclerosis:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 21366911 22236384 22277374
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19127447 19603590
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis

Genetic tests related to Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 28

Anatomical Context for Multiple Sclerosis

MalaCards organs/tissues related to Multiple Sclerosis:

38
Brain, T Cells, Spinal Cord, Testes, Bone, Monocytes, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis:
# Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis

Articles related to Multiple Sclerosis:

(show top 50) (show all 5942)
# Title Authors Year
1
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. ( 29087462 )
2018
2
Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. ( 29390025 )
2018
3
Looking into cognitive impairment in primary-progressive multiple sclerosis. ( 29053884 )
2018
4
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. ( 29363337 )
2018
5
Biopsy-proven multiple sclerosis in an adult patient with atypical craniometaphyseal dysplasia. ( 29444796 )
2018
6
Primary CNS Lymphoma vs. Tumefactive Multiple Sclerosis: A Diagnostic Challenge. ( 29290197 )
2018
7
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. ( 29308979 )
2018
8
Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma. ( 29331745 )
2018
9
Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study. ( 29121513 )
2018
10
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
11
Association of Limb-Girdle muscular dystrophy with multiple sclerosis: A case report. ( 29387327 )
2018
12
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. ( 29393768 )
2018
13
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics. ( 29285552 )
2018
14
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. ( 29449193 )
2018
15
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). ( 29399053 )
2018
16
Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis. ( 29348591 )
2018
17
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. ( 29399054 )
2018
18
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. ( 29359614 )
2018
19
Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis. ( 29306401 )
2018
20
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. ( 29442178 )
2018
21
Cladribine for multiple sclerosis. ( 29449328 )
2018
22
Gut microbiome and pediatric multiple sclerosis. ( 29307301 )
2018
23
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy. ( 29343163 )
2018
24
LIF and multiple sclerosis: One protein with two healing properties. ( 29448112 )
2018
25
Facial Myokymia and Hemifacial Spasm in Multiple Sclerosis: A Descriptive Study on Clinical Features and Treatment Outcomes. ( 29266036 )
2018
26
Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. ( 29333935 )
2018
27
Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration. ( 29429076 )
2018
28
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
29
Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases. ( 29283135 )
2018
30
Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. ( 29449827 )
2018
31
Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? ( 29411688 )
2018
32
Pediatric Multiple Sclerosis: From Recognition to Practical Clinical Management. ( 29157395 )
2018
33
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). ( 29431876 )
2018
34
Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224]. ( 29449007 )
2018
35
Biomarkers identification for PML monitoring, during Natalizumab (TysabriAr) treatment in Relapsing-Remitting Multiple Sclerosis. ( 29353737 )
2018
36
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. ( 29406907 )
2018
37
Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report. ( 29452449 )
2018
38
Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. ( 29297273 )
2018
39
A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies. ( 29195113 )
2018
40
Psychological Shift in Partners of People with Multiple Sclerosis Who Undertake Lifestyle Modification: An Interpretive Phenomenological Study. ( 29445346 )
2018
41
Multiple sclerosis or "inflammatory CADASIL?": Case Report and review of the literature. ( 29449082 )
2018
42
Search for new biomarkers of pediatric multiple sclerosis: application of immunoglobulin free light chain analysis. ( 29408796 )
2018
43
Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2A Lesion Load : AA 3-Tesla Magnetic Resonance Imaging Study. ( 29299614 )
2018
44
Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. ( 29316044 )
2018
45
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. ( 29451440 )
2018
46
Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients. ( 29449691 )
2018
47
Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis. ( 29446144 )
2018
48
Dual-Tasking in Multiple Sclerosis - Implications for a Cognitive Screening Instrument. ( 29445335 )
2018
49
An electroglottographical analysis-based discriminant function model differentiating multiple sclerosis patients from healthy controls. ( 29450761 )
2018
50
Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. ( 29284602 )
2018